Basic Duphaston Information

• INN (International Nonproprietary Name): Dydrogesterone
• Brand Names Available In Canada (English): not specified
• ATC Code: G03DB01
• Forms & Dosages: Tablet, 10 mg, blisters of 20 tablets
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: Prescription-only (Rx)

Key Findings From Recent Trials

Are patients asking whether recent studies support using dydrogesterone for miscarriage prevention and luteal support?

Canadian real-world analyses using provincial electronic medical records (2022–2024) and international randomised controlled trials and meta-analyses (2022–2024) emphasise dydrogesterone’s role in luteal-phase support and recurrent miscarriage prevention.

Evidence consistently shows benefits for pregnancy continuation in early threatened miscarriage cohorts when dydrogesterone is compared with placebo or expectant management, with several multicentre trials reporting improved live-birth or pregnancy-maintenance signals.

Effect sizes varied by baseline risk across studies, meaning higher‑risk groups often show clearer benefit than low‑risk groups.

Main trial endpoints included pregnancy continuation to 12–20 weeks and live birth, while secondary outcomes included bleeding, preterm birth and neonatal outcomes.

Most recent studies report no increase in congenital malformations associated with dydrogesterone exposure in early pregnancy cohorts.

Post‑marketing surveillance from 2022–2024 and pooled safety analyses indicate low rates of serious adverse events.

Common adverse events remained headache, nausea and spotting, and rare hepatic safety signals were noted — with severe liver disease listed as an absolute contraindication in the product monograph.

Trials and registries referenced dydrogesterone given as oral 10 mg tablets (Duphaston packaging: blisters of 20), which is consistent with product-info dosing in protocols for luteal support and recurrent miscarriage.

Major 2022–2025 Canadian & Global Studies

Which studies should clinicians read first when evaluating the evidence?

Recent Canadian real-world analyses (2022–2024) used provincial EMR datasets to assess pregnancy outcomes following dydrogesterone exposure in early threatened miscarriage and habitual abortion cohorts.

International randomised controlled trials and meta-analyses from 2022–2024 provided the most robust comparative data versus placebo or expectant management for miscarriage prevention.

Multicentre trials reported signals for improved pregnancy maintenance and live birth, though heterogeneity in baseline risk and protocol timing affected pooled estimates.

Clinicians should prioritise RCTs and well‑conducted registry analyses when weighing treatment options for luteal support in ART and for recurrent miscarriage protocols.

Main Outcomes

What outcomes did trials measure and why do they matter clinically?

Primary endpoints were pregnancy continuation to 12–20 weeks and live birth, which directly reflect clinical goals for patients presenting with threatened miscarriage.

Secondary endpoints included bleeding, preterm birth and neonatal outcomes to capture maternal and foetal safety signals.

Across trials and pooled analyses, no consistent increase in congenital malformations was observed with dydrogesterone exposure in early pregnancy cohorts.

Clinicians should counsel patients that the key measurable benefit is higher rates of pregnancy continuation in selected high‑risk groups, rather than guaranteed prevention of loss in every case.

Safety Observations

Are there any safety red flags clinicians must know?

Post‑marketing surveillance (2022–2024) and pooled safety reports indicate low absolute rates of serious adverse events with dydrogesterone at standard doses given as oral 10 mg tablets.

Common adverse effects reported included headache, nausea and spotting, which are generally mild and self‑limited.

Rare hepatic safety signals were observed and product monographs list active or severe liver disease as an absolute contraindication.

Overall tolerability in trials and registries supported continued use in settings such as ART and early pregnancy when clinically indicated and monitored.

Clinical Mechanism Of Action

How does dydrogesterone work, in simple terms and for clinicians who want the molecular details?

Layman’s Explanation

Dydrogesterone is a synthetic progestogen that mimics many of natural progesterone’s actions on the uterus.

It stabilizes the endometrium, reduces uterine contractility and supports early pregnancy without strong androgenic or glucocorticoid effects.

At standard doses it preserves ovulation and is administered orally as Duphaston 10 mg tablets in the formulations discussed here.

Scientific Breakdown

What receptor and pharmacology details matter to prescribers?

Dydrogesterone binds selectively to progesterone receptors (PR‑A and PR‑B) and modulates endometrial gene expression that favours secretory transformation and implantation support.

It reduces inflammatory and contractile mediators in the endometrium, which is relevant to preventing early pregnancy loss in some clinical scenarios.

Pharmacokinetically it is well absorbed after oral dosing and is metabolised in the liver, with no branded vaginal or injectable formulations marketed.

The ATC classification G03DB01 places it among plain progestogens and confirms its therapeutic class for clinician reference.

Pharmacology Notes Relevant To Clinicians

What distinguishes dydrogesterone from older progestins in practice?

Lack of significant androgenic, oestrogenic or glucocorticoid activity differentiates dydrogesterone from some older progestins and contributes to a favourable side‑effect profile.

This pharmacologic selectivity has informed its use in assisted reproductive techniques and protocols for threatened or recurrent miscarriage.

Because systemic hepatic metabolism is involved, avoid in severe liver disease and exercise usual caution with polypharmacy that affects steroid pathways.

Scope Of Approved & Off-Label Use

Can prescribers in Canada rely on Health Canada approvals and how is off‑label use approached?

Health Canada Approvals (DIN-Based)

Clinicians must confirm Health Canada registration and the Drug Identification Number (DIN) before routine prescribing and dispensing for formulary coverage.

Product‑info shows Duphaston is registered in many countries internationally but documentation in the RAW_DATA does not specify registration in Canada.

If Duphaston is not listed on the Canadian Drug Product Database prescribers may use importation protocols or consider alternative, DIN‑approved progestogens such as micronized progesterone.

Notable Off-Label Trends In Canadian Practice

How are Canadian clinicians actually using dydrogesterone off‑label?

Common off‑label uses in Canada include luteal‑phase support in IVF/ICSI cycles, management of recurrent miscarriage and select non‑contraceptive indications such as endometriosis or dysfunctional uterine bleeding when other agents are contraindicated.

Provincial formularies differ: coverage under Ontario Drug Benefit, BC PharmaCare and RAMQ depends on DIN listing and indication‑specific criteria, and compassionate or exceptional access pathways are sometimes used.

Dosage Strategy

What dosing schedules should prescribers and pharmacists be aware of for common indications?

General Dosing Per Health Canada Monographs

Typical adult regimens from product information include 10 mg once to twice daily depending on indication.

For secondary amenorrhea or dysfunctional bleeding the standard is 10 mg twice daily, often given on cycle days 11–25 or as directed.

For luteal support typical practice uses 10 mg daily or protocols provided by ART clinics.

Condition-Specific Dosing Adjustments

How are regimens adapted for threatened abortion and habitual abortion?

Threatened abortion regimens reported in the product information and clinical practice sometimes use an initial loading dose (for example, 40 mg initially) followed by 10 mg every 8 hours and then maintenance dosing as indicated.

For habitual abortion many protocols use 10 mg daily continued through at least week 20 of pregnancy where dydrogesterone is chosen.

Practical Prescribing Tips

What should pharmacists document and patients be told?

• Start timing: Align start day to cycle or embryo transfer timing and confirm ART clinic instructions.
• Duration: Clarify planned stop date and follow‑up with obstetric or fertility clinic.
• Missed doses: Advise not to double doses if a dose is missed.
• Hepatic caution: Avoid in severe liver disease per product monograph.

Safety Protocols

What are absolute contraindications and which adverse effects require monitoring?

Contraindications (Canadian Advisories)

Absolute contraindications in the product information include known allergy to dydrogesterone, progestogen‑dependent tumours, active or severe liver disease and undiagnosed vaginal bleeding.

Prescribers in Canada should evaluate these before prescribing and document clinical rationale when requesting provincial coverage.

Adverse Effects (Post‑Market Reports)

Common adverse effects reported include breast tenderness, headache or migraine, nausea, abdominal discomfort, spotting and fatigue.

Rare events can include oedema and mood changes, and a history of depression is a relative contraindication that warrants closer monitoring.

Severe hepatic events are rare but listed and mean the drug should be avoided in severe hepatic impairment.

Monitoring And Reporting

How should clinicians and pharmacists report and counsel?

Report serious adverse drug reactions to Health Canada’s Canada Vigilance Program and counsel patients on warning signs that require urgent review such as severe abdominal pain, jaundice or signs of venous thromboembolism.

Interaction Mapping

Which drugs and foods change dydrogesterone exposure or clinical effect?

Food Interactions Common In Canadian Diet

No major food‑drug interactions are reported in the product information for dydrogesterone.

Routine Canadian dietary patterns, including fatty meals or moderate alcohol, do not require specific timing adjustments for dydrogesterone; counsel on alcohol moderation during pregnancy as standard practice.

Drug Combinations Flagged By Health Canada

Strong enzyme inducers such as rifampin or certain antiepileptic drugs may increase steroid metabolism and reduce progestogen exposure, potentially lowering clinical effect.

Concomitant use with other hormonal therapies requires evaluation for additive effects and thromboembolic risk should be assessed when combining with estrogens.

Pharmacy Checklist

Use a standard medication reconciliation to screen for enzyme inducers/inhibitors, anticoagulants and psychotropic drugs, and document counselling on missed doses and interaction risks for provincial formulary submissions.

Patient Experience Analysis

What are patients in Canada telling pharmacists about using dydrogesterone?

Canadian Survey Data

Provincial patient‑reported outcome measures and clinic audits (2022–2024) indicate most patients find dydrogesterone tolerability similar to other oral progestogens.

Primary patient‑reported benefits include reduced bleeding and a perceived sense of pregnancy support in early pregnancy cohorts, which can improve psychological wellbeing during threatened miscarriage.

Adherence tends to be high when cost and provincial coverage are clarified prior to dispensing.

Forum & Community Pharmacy Trends

Community pharmacists at national chains report common patient queries about availability, price and safety in pregnancy.

Online forum discussions frequently compare dydrogesterone with micronized progesterone (Prometrium) and raise questions about importation versus domestic DIN‑approved products.

Counselling Priorities

Key counselling points are timing and duration of dosing, expected side effects, storage below 30°C and when to seek urgent care.

Provide bilingual materials where appropriate in Quebec and document counselling for provincial reimbursement requests.

Distribution & Pricing Landscape

How easy is it for Canadian patients to obtain Duphaston and what influences price?

National Pharmacy Chains

Availability in Canada depends on DIN status and distributor agreements, and larger chains may source product via Abbott/AbbVie or managed import programmes.

Community pharmacists verify DIN and provincial formulary listing before dispensing to determine coverage and out‑of‑pocket costs.

Online Pharmacy Availability & Provincial Restrictions

Canadian online pharmacies list only DIN‑approved products for routine sale; where Duphaston lacks a Canadian DIN patients may be offered therapeutic alternatives or special importation routes.

Provincial formularies require DIN and indication‑specific criteria for coverage and exceptional access applications are sometimes necessary.

In our online pharmacy, duphaston is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross-Border US Comparisons

Duphaston was discontinued in the USA and withdrawn in the UK, which affects cross‑border availability and complicates simple price comparisons with US generics.

Price transparency is essential: compare provincial reimbursement against out‑of‑pocket costs when counselling patients.

Alternative Options

What are practical alternatives when dydrogesterone is unavailable or not suitable?

Comparison Of DIN-Approved Alternatives

Key alternatives include micronized progesterone (Prometrium), medroxyprogesterone acetate (Provera), and norethisterone, each with differing formulations and ATC classes.

Micronized progesterone is available in oral and vaginal forms and is commonly used for luteal support and hormone replacement therapy.

Pros And Cons Checklist

• Dydrogesterone (Duphaston): Pros — oral only, selective progestogen with minimal androgenic activity and long clinical history; Cons — limited formulations and variable availability in Canada.
• Micronized Progesterone (Prometrium): Pros — multiple formulations including vaginal, widely available and DIN‑listed; Cons — can cause sedation and administration route may bother some patients.
• Medroxyprogesterone: Pros — strong availability; Cons — different side‑effect profile and potential androgenic effects compared with dydrogesterone.

Decision Framework

Match the formulation to the indication (ART, miscarriage prevention, HRT), patient preference for oral versus vaginal administration, hepatic status and formulary coverage when choosing an alternative.

Regulatory Status

Which regulatory steps matter for prescribing, importing and reimbursement?

Health Canada Approval Process

Prescribers should confirm Health Canada marketing authorisation and DIN before routine dispensing and for public plan submissions.

If Duphaston lacks a Canadian DIN clinicians may pursue the Special Access Programme or importation under Health Canada guidance for individual patients.

DIN And Bilingual Labelling Rules

Canadian rules require a DIN on marketed packaging and bilingual labelling where applicable; imported medicines should comply with labelling expectations and pharmacies must document source, batch and patient consent when supplying non‑DIN product.

Provincial Payer Considerations

Public plans typically require DIN and indication‑specific criteria for coverage, and prior authorizations or exceptional access applications should include clear clinical rationale supporting the use of dydrogesterone over DIN‑listed alternatives.

Consolidated FAQ

Which quick questions do patients and clinicians ask most often?

Q1: Is Duphaston available in Canada and covered by provincial plans?

A: Availability depends on DIN status and supplier agreements; check Health Canada’s Drug Product Database and provincial formularies (ODB, PharmaCare, RAMQ). If not DIN‑listed, access may require importation or alternative therapy.

Q2: Is dydrogesterone safe in early pregnancy?

A: Clinical trials and post‑marketing data show safety signals comparable to other progestogens for miscarriage prevention, and monitoring per obstetric guidance is recommended while avoiding use in severe liver disease.

Q3: How should I store Duphaston at home?

A: Store below 30°C in the original blister packaging, away from moisture and heat, and keep out of reach of children.

Q4: Can dydrogesterone be used with IVF protocols?

A: Yes — it is commonly used for luteal‑phase support; align dosing with embryo transfer timing per clinic protocol.

Q5: What are common side effects?

A: Breast tenderness, headache, nausea, spotting and fatigue are common; report severe events to Health Canada.

Visual Guide

What visuals help patients and clinic staff understand dosing, access and storage?

Recommended infographics include dosage timelines for luteal support and threatened miscarriage, a provincial coverage flowchart (DIN check → formulary eligibility → special access) and a pharmacy supply map contrasting chain stock, compounding and import options.

Dosage infographic elements should show the standard 10 mg tablet in a blister of 20, regimen blocks (10 mg daily vs 10 mg twice daily), and a missed‑dose action box advising not to double the dose.

Coverage visuals should include icons for Ontario Drug Benefit, BC PharmaCare and RAMQ with steps for prior authorization and exceptional access, plus a bilingual labelling reminder for Quebec materials.

Storage & Transport

How should pharmacies and patients store and ship Duphaston across Canada?

Canadian Household Guidelines

Store tablets below 30°C in their original blister to protect from moisture and keep them away from bathroom humidity and direct heat.

Advise pregnant patients to store medications safely to prevent accidental exposure by other household members.

Cold-Chain Storage Where Applicable

Dydrogesterone tablets do not require cold‑chain storage, but avoid exposure to extreme heat during summer shipping across Canada.

Pharmacies should consider insulated packaging for long‑distance courier shipments during peak summer months to prevent temperatures above 30°C.

Pharmacy Logistics Checklist

On receipt verify batch and expiry, retain supplier documentation for imported lots, store stock in ambient rooms with temperature monitoring and advise patients to carry medication in hand luggage rather than a car trunk during travel in hot weather.

Guidelines For Proper Use

What final checks should pharmacists perform before dispensing Duphaston?

Advice From Canadian Pharmacists

Verify DIN and indication, screen for contraindications such as severe liver disease and progestogen‑dependent tumours, and check for interacting medications including enzyme inducers and anticoagulants.

Counsel patients on dosing timing, missed‑dose instructions, side effects and when to seek urgent care, and document counselling especially for pregnancy use and prior authorizations.

Provincial Health Authority Guidance

Follow provincial formularies for coverage criteria and submit prior authorization with supporting clinical documentation when required.

Use bilingual patient materials in Quebec and align management with provincial perinatal and ART protocols.

Practical Patient Checklist

Before the patient leaves the pharmacy confirm the prescription details (dose and duration), storage guidance (<30°C), absence of severe hepatic disease, follow‑up appointments and provide instructions for reporting adverse events to Health Canada (Canada Vigilance).

Delivery Across Canada (English)

Concluding Notes For Clinicians And Pharmacists

What final practical points help clinicians and pharmacists support patients choosing dydrogesterone?

Dydrogesterone (INN) is supplied internationally as Duphaston 10 mg tablets in blisters of 20 and is classified under ATC G03DB01 as a plain progestogen with a long clinical history since 1961.

Use in Canada depends on DIN status and provincial formulary rules, and where Duphaston is not DIN‑listed consider micronized progesterone or other DIN‑approved alternatives for luteal support and miscarriage prevention.

Document contraindications, counsel on common adverse effects and storage (<30°C), and advise patients to seek urgent care for warning signs such as jaundice, severe abdominal pain or thromboembolic symptoms.

For formulary submissions include clear clinical rationale, source documentation for imported product if relevant, and evidence from RCTs and registries supporting use in high‑risk miscarriage or ART protocols.

Pharmacists should remain a first contact for questions about dosing schedules, interactions with enzyme inducers and provincial coverage pathways, and should report adverse events to Health Canada’s Canada Vigilance program as required.